Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SMOFLipid versus ClinOleic for parenteral nutrition-associated cholestasis risk in very preterm neonates
ACTRN12617000883314Phase 4Not yet recruiting
- Sponsor
- Nepean Hospital Neonatal Intensive Care Unit
- Start
- Jun 2017
- Modality
- Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, randomised trial in parenteral nutrition-associated cholestasis (PNAC) and intestinal failure-associated liver disease (IFALD) comparing SMOFLipid 20% with ClinOleic 20% (2 arms). Primary endpoint: Levels of long-chain polyunsaturated fatty acids in plasma and red cell membrane. Planned start Jun 2017; status: not yet recruiting.
02
Drugs
SMOFlipidClinoleic
03
Conditions
parenteral nutrition-associated cholestasis (PNAC)intestinal failure-associated liver disease (IFALD)
Beyond the preview
Go deeper on ACTRN12617000883314.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12617000883314.